Skip to main content

Table 3 Reported vaginal symptoms post-treatment

From: Testing the regulatory framework in South Africa – a single-blind randomized pilot trial of commercial probiotic supplementation to standard therapy in women with bacterial vaginosis

 

Month 1

Month 3

SOC

Intervention

RR (95%CI)a

p-value

SOC

Intervention

RR (95%CI)a

p-value

Discharge improvement [%(n/N)]

83.3 (10/11)

77.8 (14/18)

0.86 (0.63–1.17)

p = 0.324

83.3 (10/12)

81.3 (13/16)

0.96 (0.69–1.34)

p = 0.886

Less discharge

90.0 (9/10)

78.6 (11/14)

0.87 (0.62–1.23)

p = 0.438

90.0 (9/10)

61.5 (8/13)

0.68 (0.42–1.10)

p = 0.118

Change in colour

50.0 (5/10)

57.1 (8/14)

1.14 (0.53–2.46)

p = 0.733

70.0 (7/10)

46.2 (6/13)

0.66 (0.32–1.35)

p = 0.253

Change in smell

70.0 (7/10)

71.4 (10/14)

1.02 (0.60–1.72)

p = 0.940

80.0 (8/10)

61.5 (8/13)

0.77 (0.45–1.31)

p = 0.332

  1. aRelative Risk (RR) and 95% Confidence interval (CI) were used to compare groups